*Data are presented as the means (standard deviations), median (IQR), or n (%).
Abbreviations: ALD, alcohol-associated liver disease; ALT, alanine aminotransferase; AST, aspartate transaminase; CSPH, clinically significant portal hypertension; HVPG, hepatic venous pressure gradient; LSM, liver stiffness measurement; NAFLD, non-alcoholic fatty liver disease; PSM, propensity score matching.
Supplementary Figure 1. Flow chart of the study selection methodology.
Supplementary Figure 2. Risk of bias and concerns regarding the applicability of the included studies based on QUADAS-2 criteria.
Supplementary Figure 3. Flowchart of patient recruitment in the different cohorts.
Supplementary Figure 4.Performance of CSPH risk model for detection of clinically significant portal hypertension in viral cohort and non-viral cohort.
Supplementary Figure 5. Performance of CSPH risk model, ANTICIPATE model and Baveno VII criteria in follow-up cohort.
Supplementary Figure 6. Ascites according to treatment group. A: cumulative incidence of ascites before propensity score matching (PSM); B: cumulative incidence of ascites after PSM.